X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare AJANTA PHARMA with ASTRAZENECA PHARMA - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs ASTRAZENECA PHARMA - Comparison Results

ASTRAZENECA PHARMA 
   Change

AstraZeneca Pharma India Limited (APIL) is a 90% subsidiary of the UK based AstraZeneca Pharmaceuticals, which is one of the world's leading pharma companies. APIL has interests in the six crucial areas of cardiovascular, respiratory, maternal health... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA ASTRAZENECA PHARMA AJANTA PHARMA/
ASTRAZENECA PHARMA
 
P/E (TTM) x 20.6 154.7 13.3% View Chart
P/BV x 4.8 24.0 19.9% View Chart
Dividend Yield % 0.0 0.0 -  

Financials

 AJANTA PHARMA   ASTRAZENECA PHARMA
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-18
ASTRAZENECA PHARMA
Mar-14
AJANTA PHARMA/
ASTRAZENECA PHARMA
5-Yr Chart
Click to enlarge
High Rs1,8181,285 141.5%   
Low Rs1,106634 174.4%   
Sales per share (Unadj.) Rs239.5189.6 126.3%  
Earnings per share (Unadj.) Rs52.8-0.2 -25,929.6%  
Cash flow per share (Unadj.) Rs59.53.8 1,547.8%  
Dividends per share (Unadj.) Rs00-  
Dividend yield (eoy) %00-  
Book value per share (Unadj.) Rs230.068.6 335.0%  
Shares outstanding (eoy) m88.7725.00 355.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x6.15.1 120.6%   
Avg P/E ratio x27.7-4,712.7 -0.6%  
P/CF ratio (eoy) x24.6249.6 9.8%  
Price / Book Value ratio x6.414.0 45.5%  
Dividend payout %00-   
Avg Mkt Cap Rs m129,78223,988 541.0%   
No. of employees `0006.81.6 435.9%   
Total wages/salary Rs m3,7651,605 234.6%   
Avg. sales/employee Rs Th3,128.43,040.2 102.9%   
Avg. wages/employee Rs Th554.01,029.2 53.8%   
Avg. net profit/employee Rs Th689.7-3.3 -21,124.1%   
INCOME DATA
Net Sales Rs m21,2584,740 448.5%  
Other income Rs m24292 262.3%   
Total revenues Rs m21,4994,832 445.0%   
Gross profit Rs m6,584-130 -5,072.3%  
Depreciation Rs m596101 588.8%   
Interest Rs m40-   
Profit before tax Rs m6,226-139 -4,482.0%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0139 0.0%   
Tax Rs m1,5395 30,237.7%   
Profit after tax Rs m4,686-5 -92,070.7%  
Gross profit margin %31.0-2.7 -1,131.0%  
Effective tax rate %24.7-3.7 -674.6%   
Net profit margin %22.0-0.1 -20,528.6%  
BALANCE SHEET DATA
Current assets Rs m12,2362,726 448.8%   
Current liabilities Rs m3,4612,435 142.1%   
Net working cap to sales %41.36.1 671.5%  
Current ratio x3.51.1 315.8%  
Inventory Days Days6074 81.6%  
Debtors Days Days8441 207.3%  
Net fixed assets Rs m11,1401,035 1,076.0%   
Share capital Rs m17750 353.8%   
"Free" reserves Rs m20,237942 2,147.4%   
Net worth Rs m20,4141,716 1,189.6%   
Long term debt Rs m100-   
Total assets Rs m24,4864,156 589.2%  
Interest coverage x1,519.4NM-  
Debt to equity ratio x00-  
Sales to assets ratio x0.91.1 76.1%   
Return on assets %19.2-0.1 -15,640.9%  
Return on equity %23.0-0.3 -7,739.6%  
Return on capital %30.50-  
Exports to sales %05.7 0.0%   
Imports to sales %06.5 0.0%   
Exports (fob) Rs mNA270 0.0%   
Imports (cif) Rs mNA306 0.0%   
Fx inflow Rs m11,667375 3,114.6%   
Fx outflow Rs m1,616470 343.6%   
Net fx Rs m10,052-96 -10,519.9%   
CASH FLOW
From Operations Rs m2,854-8 -35,237.0%  
From Investments Rs m-2,604-146 1,787.3%  
From Financial Activity Rs m-2862 -0.2%  
Net Cashflow Rs m248709 35.0%  

Share Holding

Indian Promoters % 73.8 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 1.6 0.3 516.7%  
FIIs % 7.6 15.7 48.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 9.1 186.8%  
Shareholders   20,968 12,856 163.1%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ALEMBIC PHARMA  FRESENIUS KABI ONCO.  TTK HEALTHCARE  TORRENT PHARMA  STRIDES PHARMA SCIENCE  

Compare AJANTA PHARMA With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 300 Points Lower; Metal and IT Stocks Witness Selling(Closing)

Share markets in India witnessed most of the selling pressure during closing hours and ended their trading session on a negative note.

Related Views on News

AJANTA PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 4.9% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, AJANTA PHARMA has posted a net profit of Rs 1 bn (down 4.9% YoY). Sales on the other hand came in at Rs 5 bn (up 0.7% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

ASTRAZENECA PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 10.3% (Quarterly Result Update)

Aug 21, 2018 | Updated on Aug 21, 2018

For the quarter ended June 2018, ASTRAZENECA PHARMA has posted a net profit of Rs 64 m (up 10.3% YoY). Sales on the other hand came in at Rs 2 bn (up 25.7% YoY). Read on for a complete analysis of ASTRAZENECA PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

These Are the Kind of Blue Chips You Should Invest In(The 5 Minute Wrapup)

Nov 9, 2018

All blue chip companies are large caps but all large caps are not blue chips.

5G Stocks: Cutting-Edge Technology that Could Make You Very Rich...(Profit Hunter)

Nov 12, 2018

A brand new technology and a stock that could soar with the upcoming 5G rollout.

Why the Realty Sector's Recovery Has Been Delayed(Sector Info)

Nov 15, 2018

NBFC and IL&FS crisis have worsened the realty sector woes. Is there a light at the end of the tunnel for real estate sector?

This Was a Large Cap. But Was It Safe?(Chart Of The Day)

Nov 9, 2018

Investing in large caps is not always safe. Consider the right metrics to judge the safety and quality of large caps.

Investing In Small Cap Funds? Read This Before You Invest(Outside View)

Nov 19, 2018

PersonalFN explains the care to take when investing in small-cap funds and the approach to follow.

More

Small Investments
BIG Returns

Zero To Millions Guide 2019
Get our special report, Zero To Millions
(2019 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Nov 20, 2018 (Close)

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 5-YR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS